Publications

Papers Published or in Press

  1. Mohammad KS, Bdesha AS, Snell ME, Witherow RO, Coleman DV. Phase contrast microscopic examination of urinary erythrocytes to localize source of bleeding: An overlooked technique. J Clin Path, 1993, 46:642- 645. Cited 9 times, IF=2.60, Rank 26 of 69 pathology journals.
  2. Mohammad SK, Day FA, Neufeld, DA. Bone growth is induced by nail transplantation in amputated proximal phalanges. Calcified Tissue Intl, (1999) 65:408-410. Cited 8 times, IF=2.94, Rank 49 of 93 Endocrinology & Metabolism journals.
  3. Neufeld DA, Mohammad KS.Regeneration of bone.    In: Nature Encyclopedia of Life Sciences. London: Nature Publishing Group. http://www.els.net/ (May 1999) [doi:10.1038/npg.els.0001107].
  4. Mohammad  KS,  Neufeld  DA.          Denervation  retards  but  does  not  prevent  toetip  regeneration. Wound Repair  and  Regeneration,  (2000)  8(4):277-281.   Cited  2  times, IF=2.55,  Rank  15  of  43 Dermatology journals.
  5. Neufeld DA, Mohammad KS. Fluorescent bone viewed through toenails of living animals: a method to observe bone regrowth. Biotechnique and Histochemistry, Nov 2000, 75(6):259-263. Cited 1 times, IF=0.84, Rank 115 of 144 Biotechnology & Applied microbiology journals.
  6. Guise TA, Yin JJ, Mohammad KS.   Role of endothelin-1 (ET-1) in osteoblastic bone metastases.
    Can    cer, Feb 2003, 97(S3) 779-784. Cited 62 times, IF=5.57, Rank 19 of 143 Oncology journals.
  7. Koss CH, Karaplis AC, Goltzman D, Mohammad KS, Guise TA, Pollak MR. Mice lacking calcium- sensing receptor survive in the absence of parathyroid hormone. J Clin Investig, April 2003, 111:7(1021-028). Cover.  Cited 63 times, IF=17.089, Rank 2 of 82 Medicine research & experimental journals.
  8. Yin JJ, Mohammad KS, Kakonen SM, Harris S, Wu-Wong JR, Wessale JL, Padley RJ, Garrett IR, Chirgwin JM, Guise TA. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. PNAS, Sep 16, 2003, 100(19):10954-10959. Cited 95 times, IF=10.22, Rank 3 of 42 Multidisciplinary journals.
  9. Mohammad KS, Guise TA. Mechanisms of Osteoblastic Metastases: Role of Endothelin-1. Clin Ortho and Related Res, Oct 2003, 1(415S) Supplement:S67-S74. Cited 11 times, IF=2.48, Rank 16 of 49 Orthopedics journals.
  10. Guise TA, Mohammad KS, Käkönen SM, Chirgwin JM.  Molecular mechanisms of bone metastases.
    American Society of Clinical Oncology Educational Book from 39th Annual Meeting, 77-80, 2003.
  11. Maier B, Gluba W, Bernier B, Turner T, Mohammad K, Guise T, Sutherland A, Thorner M, Scrable H. Modulation of mammalian life-span by the short isoform of p53. Genes and Development 2004, 18:306-319. Cited 176 times, IF=14.42, Rank 3 of 138 Genetics & Heredity journals.
  12. Chirgwin JM, Mohammad KS, Guise TA. Tumor-bone cellular interactions in skeletal metastases. J Musculoskeletal and Neuronal Interactions 2004, 4(3):308-318.
  13. Neufeld D, Hosman S, Yescas T, Mohammad KS, Day F, Said S. Actin fiber patterns detected by alexafluor 488 phalloidin suggest similar migration in regenerating and nonregenerating rodent toes. Anatom Record, 2004, 278A(1):450-453. Cited 2 times, IF=1.807, Rank 4 of 15 Anatomy & Morphology journals.
  14. Guise TA, Mohammad KS. Endothelins in bone cancer metastases, Chapter (9) pp 197-212 in“The Biology of Skeletal Metastases.” Edited by Evan Keller and Leland Chung. 2004 Kluwer Academic Publishers.
  15. Clines GA, Mohammad KS, Chirgwin JM, Guise TA. Regulation of  Dickkopf  homolog  (DKK1) expression by endothelin-1 (ET-1): Implications in the pathogenesis of osteoblastic metastases. JBMR 19 (S1) S133, 2004.
  16. Bendre MS, Margulies AG, Walser B, Akel NS, Bhattacharrya S, Skinner RA, Swain F, Ramani FV, Mohammad KS, Wessner LL, Martinez A, Guise TA, Chirgwin JM, Gaddy D, Suva LJ. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor- B ligand pathway. Cancer Res, 2005 65: 11001-11009. Cited 51 times, IF=7.98, Rank 12 of 143 Oncology journals.
  17. Clines GA, Mohammad KS, Bao Y, Stephens OW, Suva LJ, Shaughnessy Jr JD, Fox JW, Chirgwin JM, Guise TA. Dickkopf Homolog 1 Mediates Endothelin-1-Stimulated New Bone Formation. Molecular Endocrinol, 2007, 21(2):486-496. Cited 15 time, IF=5.43, Rank 16 of 93 Endocrinology & Metabolism journals.
  18. Guise.TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, Vessella R, Corey E, Padalecki S, Suva L, Chirgwin JM. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res, 2006;12(6213s -6216s). Cited 20 times, IF=6.64, Rank 16 of 143 Oncology journals.
  19. Javelaud D, Mohammad KS, McKenna CR, Niewolna M, Andre J, Delmas V, Larue L, Guise TA, Mauviel A. Stable overexpression of Smad7 in human melanoma cells inhibits bone metastasis in vivo J of  Investigative Dermatology 126: 82-82 Suppl. 3, Aug. 2006. Cited ** times, IF=5.24, Rank 1 of 43 Dermatology journals
  20. Javelaud D**, Mohammad KS**, McKenna CR, Fournier P, Luciani F, Niewolna M, André J, Delmas V, Larue L, Guise TA, Mauviel A. Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. Cancer Res. 2007 Mar, 67(5):2317-24. ** Contributed equally to this work. Cited 26 times, IF=7.98, Rank 12 of 143 Oncology journals.
  21. Mohammad KS, J. Chirgwin JM, Guise TA. Assessing New Bone Formation in Neonatal Calvarial Organ Culture, Chapter (3) pp 37-50 in “Osteoporosis Methods and Protocols”. 2008 Humana Press.
  22. Mohammad KS, Chen C, Balooch G, Stebbins E, McKenna CR, Walton H, Niewolna M, Peng X, Nguyen D, Ionova-Martin SS, Bracey JW, Hogue WR, Wong DH, Ritchie RO, Suva LJ, Derynck R, Guise TA, Alliston T. Pharmacologic inhibition of the TGF-β type I receptor kinase has anabolic and anti- catabolic effects on bone. Proceedings of the Library of Science ONE PLoS ONE 2009 Volume 4, Issue 4 e5275. Cited 2 times
  23. Dunn LK, Mohammad KS, Fournier PG, McKenna CR, Davis HW, Niewolna M, Peng XH, Chirgwin JM, Guise TA. Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. Proceedings of the Library of Science ONE PLoS ONE 2009 Volume 4, Issue 9 e6896
  24. Mohammad KS, Fournier PG, Guise TA, Chirgwin JM. Agents Targeting Prostate Cancer Bone Metastasis. Anticancer Agents Med Chem. 2009 Dec 1;9(10):1079-88.
  25. Alexaki VI, Javelaud D, Van Kempen LCL, Mohammad KS, Dennler S, Luciani F, Koek K, Juarez P, Goydos JS, Sibon C, Bertolotto C, Verrecchia F, Saule S, Delmas V, Ballotti R, Larue L, Saiag P, Guise TA, Mauviel A.  GLI2, A TGF-β inducible target, promotes Melanoma invasion and metastases. Journal of the National Cancer Institute JNCI, 2010 Aug 4;102(15):1148-59
  26. Mohammad KS, Javelaud D, Fournier PG, Niewolna M, McKenna CR, Peng XH, Duong V, Dunn LK, Mauviel A, Guise TA. TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Res. 2011 Jan 1;71(1):175-84
  27. Kim T, Park H, Yue W, Wang JP, Atkins KA, Zhang Z, Rogan EG, Cavalieri EL, Mohammad KS, Kim S, Santen RJ, Aiyar SE. Tetra-methoxystilbene modulates ductal growth of the developing murine mammary gland. Breast Cancer Res Treat. 2011 Apr;126(3):779-89.
  28. Liang H, Ma SY, Mohammad K, Guise TA, Balian G, Shen FH. The reaction of bone to tumor growth from human breast cancer cells in a rat spine single metastasis model. Spine (Phila Pa 1976). 2011 Apr 1;36(7):497-504.
  29. Javelaud D, Alexaki VI, Dennler S, Mohammad KS, Guise TA, Mauviel A. TGF-{beta}/SMAD/GLI2 Signaling Axis in Cancer Progression and Metastasis. Cancer Res. 2011 Sep 1;71(17):5606-10.
  30. Clines GA, Mohammad KS, Grunda JM, Katrina L. Clines KL, Niewolna M, McKenna CR, McKibbin CR, Yanagisawa M, Suva LJ, Chirgwin JM, and Guise TA. Regulation of postnatal trabecular bone formation by the osteoblast endothelin A receptor. JBMR, 2011 Oct;26(10):2523-36
  31. Wu X, Chen S, He Y, Rhodes SD, Mohammad KS, Li X, Yang X, Jiang L, Nalepa G, Snider P, Robling AG, Clapp DW, Conway SJ, Guise TA, Yang FC. The Haploinsufficient Hematopoietic Microenvironment Is Critical to the Pathological Fracture Repair in Murine Models of Neurofibromatosis Type 1. PLoS One. 2011;6(9):e24917
  32. Cao L, Shao M, Schilder J, Guise T, Mohammad KS, Matei D. Tissue transglutaminase links TGF-β, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene. 2012 May 17;31(20):2521-34
  33. Nickerson NK, Mohammad KS, Gilmore JL, Crismore E, Bruzzaniti A, Guise TA, Foley J. Decreased autocrine EGFR signaling in metastatic breast cancer cells inhibits tumor growth in bone and mammary fat pad. PLoS One. 2012;7(1):e30255.
  34. Pollari S, Käkönen RS, Mohammad KS, Rissanen JP, Halleen JM, Wärri A, Nissinen L, Pihlavisto M, Marjamäki A, Perälä M, Guise TA, Kallioniemi O, Käkönen SM. Heparin-like polysaccharides reduce osteolytic bone destruction and tumor growth in a mouse model of breast cancer bone metastasis. Mol Can Res 2012 May;10(5):597-604
  35. Juárez P, Mohammad KS, Yin JJ, Fournier PG, McKenna RC, Davis HW, Peng XH, Niewolna M, Javelaud D, Chirgwin JM, Mauviel A, Guise TA. Halofuginone inhibits the establishment and progression of melanoma bone metastases. Cancer Res. 2012 Dec 1;72(23):6247-56
  36. He Y, Rhodes SD, Chen S, Wu X, Yuan J, Yang X, Jiang L, Li X, Takahashi N, Xu M, Mohammad KS, Guise TA, Yang FC. c-Fms Signaling Mediates Neurofibromatosis Type-1 Osteoclast Gain-In- Functions. PLoS One. 2012;7(11):e46900 Epub 2012 Nov 7.
  37. Wright LE, Frye JB, Lukefahr AL, Timmermann BN, Mohammad KS, Guise TA, Funk JL. Curcuminoids Block TGF-β Signaling in Human Breast Cancer Cells and Limit Osteolysis in a Murine Model of Breast Cancer Bone Metastasis. J Nat Prod. 2013 Mar 22;76(3):316-21
  38. Hoggatt J, Mohammad KS, Singh P, Hoggatt AF, Chitteti BR, Speth JM, Hu P, Poteat BA, Stilger KN, Ferraro F, Silberstein L, Wong FK, Farag SS, Czader M, Milne GL, Breyer RM, Serezani CH, Scadden  DT, Guise T, Srour EF, and Pelus LM. Differential Stem and Progenitor Cell Trafficking by Prostaglandin E2. Nature. 2013 Mar 21;495(7441):365-9. doi: 10.1038/nature11929. Epub 2013 Mar 13
  39. Casimiro S, Mohammad KS, Pires R, Tato-Costa J, Alho I, Teixeira R, Carvalho A, Ribeiro S, Lipton A, Guise TA, Costa L. RANKL/RANK/MMP-1 Molecular Triad Contributes to the Metastatic Phenotype of Breast and Prostate Cancer Cells In Vitro. PLoS One. 2013 May 16;8(5):e63153
  40. Rhodes SD, Wu X, He Y, Chen S, Yang H, Staser KW, Wang J, Zhang P, Jiang C, Yokota H, Dong R, Peng X, Yang X, Murthy S, Azhar M, Mohammad KS, Xu M, Guise TA, Yang FC. Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model.
    J Bone Miner Res. 2013 Dec;28(12):2476-89.
  41. Hoggatt J, Mohammad KS, Singh P, Pelus LM. Prostaglandin E2 enhances long-term repopulation but does not permanently alter inherent stem cell competitiveness. Blood. 2013 Oct 24;122(17):2997-3000
  42. Waning DL, Mohammad KS, and Guise TA. Cancer-Associated Osteoclast Differentiation Takes a Good Look in the miR(NA)ror. Cancer Cell Volume 24, Issue 4, 14 October 2013, Pages 407–409.
  43. Chiechi A, Waning DL, Stayrook KR, Buijs JT, Guise TA, Mohammad KS. Role of TGF-β in breast cancer bone metastases. Advances in Bioscience and Biotechnology, 2013, 4, 15-30 (Open access)
  44. Alam I, Gray AK, Chu K2, Ichikawa S, Mohammad KS, Capannolo M, Capulli M, Maurizi A, Muraca M, Teti A, Econs MJ, Del Fattore A. Generation of the first autosomal dominant osteopetrosis type II (ADO2) disease models. Bone. 2014 Feb;59:66-75

Media Comments

  • Beyond the Abstract - Agents targeting prostate cancer bone metastasis, by Khalid S. Mohammad, MD, PhD, and John M. Chirgwin, PhD. Uro Today Tuesday, 08 December 2009. www.urotday.com

Khalid S. Mohammad

Associate Research Professor of Medicine

 

  • :1-317-278-6013
  • DEPARTMENTDepartment of Internal Medicine
    Division of Endocrinology & Metabolism
    Indiana University
  • COUNTRYUSA